Navigo Proteins and Eleva Announce Successful Development of an Affinity Chromatography Resin Customized for the Efficient Purification of Human Complement-Factor H
Custom Affinity Chromatography Resin Promises High Yield Purification in Clinical and Commercial GMP Downstream Processing
Navigo Proteins GmbH (“Navigo”), a premier protein engineering company, developer of affinity ligands for custom chromatography solutions, and eleva GmbH (“Eleva”), a manufacturer of superior biologics derived from its proprietary moss expression system, announce today the successful implementation of a customized affinity chromatography resin into the purification process of Eleva’s Complement- Factor H, CPV-101, for its coming clinical development.
Using Navigo’s proprietary platform, an affinity chromatography resin has been developed, which purifies enzymatically active Factor H efficiently from moss cell culture medium. The resin delivers a robust, scalable, and predictable Factor H downstream process, thereby addressing inherent challenges of conventional purification processes. The validation for clinical and commercial resin supply to support CPV-101 future development path is ongoing.
Florian Settele, Navigo’s Head of Precision Capturing®, commented: “We are delighted to be able to work together with a great Eleva team to successfully develop an innovative affinity chromatography solution for the purification of CPV-101. Our custom affinity chromatography technology immediately showed its full potential for efficient production of CPV-101 with excellent purity and yield. We are looking forward to continue our support of Eleva by delivering validated resin for production of clinical grade material.”
Sören Boller, Eleva’s Head of Downstream Process Development added: “After receiving the affinity chromatography resin for the purification of CPV-101 from Navigo, we performed numerous experiments to challenge the resin. We were amazed to see an excellent purity after only a single purification step. This powerful tool allows for flexible design of a CPV-101 purification strategy, eventually leading to a successful purification of CPV-101. We are looking forward to continuing the successful collaboration with Navigo and are excited to test the affinity resin in larger scale.”